Division of Oncology

Medicine & Life Sciences

1. Neoplasms 100%
2. Breast Neoplasms 60%
3. Therapeutics 57%
4. Survival 54%
5. Mutation 51%
6. Drug Therapy 45%
7. Multiple Myeloma 44%
8. Acute Myeloid Leukemia 43%
9. Non-Small Cell Lung Carcinoma 41%
10. T-Lymphocytes 36%
11. Genes 35%
12. Progression-Free Survival 34%
13. Bone Marrow 30%
14. Hematopoietic Stem Cells 29%
15. Genome 28%
16. Leukemia 27%
17. Rituximab 27%
18. Cell Transplantation 26%
19. Non-Hodgkin's Lymphoma 26%
20. Proteins 24%
21. Transplants 24%
22. Immunotherapy 23%
23. Stem Cells 22%
24. Granulocyte Colony-Stimulating Factor 21%
25. Hodgkin Disease 21%
26. Recurrence 21%
27. Graft vs Host Disease 21%
28. Lymphoma 20%
29. Natural Killer Cells 20%
30. Prostatic Neoplasms 20%
31. Renal Cell Carcinoma 19%
32. Clinical Trials 19%
33. Mantle-Cell Lymphoma 19%
34. Safety 18%
35. HIV-1 18%
36. Neoplasm Metastasis 18%
37. Lymphoma, Large B-Cell, Diffuse 18%
38. Pancreatic Neoplasms 18%
39. High-Throughput Nucleotide Sequencing 18%
40. Adenocarcinoma 17%
41. Myelodysplastic Syndromes 17%
42. Radiotherapy 16%
43. Confidence Intervals 16%
44. Lung Neoplasms 16%
45. Sarcoma 16%
46. Allogeneic Cells 16%
47. DNA 16%
48. Cyclophosphamide 16%
49. Follicular Lymphoma 16%
50. Growth 15%
51. Cell Line 15%
52. Triple Negative Breast Neoplasms 15%
53. Biomarkers 15%
54. Lenalidomide 14%
55. Stem Cell Transplantation 14%
56. Deltaretrovirus 14%
57. Brentuximab Vedotin 14%
58. Guidelines 14%
59. Mucopolysaccharidosis VII 14%
60. Macrophages 14%
61. Bortezomib 13%
62. Hematopoiesis 13%
63. gemcitabine 13%
64. Melanoma 13%
65. Doxorubicin 13%
66. HIV 13%
67. B-Cell Lymphoma 13%
68. Glioblastoma 13%
69. Gene Expression 13%
70. Chimeric Antigen Receptors 12%
71. Clone Cells 12%
72. Hematologic Neoplasms 12%
73. Apoptosis 12%
74. plerixafor octahydrochloride 12%
75. Population 12%
76. Docetaxel 12%
77. Paclitaxel 12%
78. Lymphocytes 11%
79. Carboplatin 11%
80. Hematopoietic Stem Cell Transplantation 11%
81. Phosphotransferases 11%
82. Cytokines 11%
83. pembrolizumab 11%
84. Heterografts 11%
85. Maintenance 11%
86. Human T-lymphotropic virus 1 11%
87. Ligands 11%
88. Hematopoietic Stem Cell Mobilization 10%
89. Neutrophils 10%
90. Bendamustine Hydrochloride 10%
91. B-Lymphocytes 10%
92. Phenotype 10%
93. Protein-Tyrosine Kinases 10%
94. Proteomics 10%
95. Bone Marrow Transplantation 10%
96. Carcinoma 10%
97. Tissue Donors 10%
98. Cisplatin 10%
99. Placebos 10%
100. Transplantation 10%